Abstract
Species of the family Enterobacteriaceae represent the most prevalent group of nosocomial pathogens. In this paper, we report the data on antimicrobial susceptibility of 1670 isolates of Enterobacteriaceae collected in 35 hospitals of 22 cities of Russia in 2013-2014 as part of the national multicenter surveillance study on antimicrobial resistance of nosocomial pathogens, «MARATHON». Enterobacteriaceae isolates jointly comprised 43.1% of all bacterial nosocomial isolates. The most abundant species were Klebsiella pneumoniae (20.7%), Escherichia coli (11.2%) and Enterobacter cloacae (2.6%). Most of the isolates were insusceptible to oxyimino-β-lactams: cefotaxime (75.6%), ceftazidime (71.9%), cefepime (72.0%) and aztreonam (72.5%). The non-susceptibility rates to carbapenems were: 6.9% to meropenem, 7.8% to doripenem, 8.5% to imipenem and 18.0% to ertapenem. The majority of carbapenem resistant isolates were K. pneumoniae. 7.8% of all isolates were found to produce carbapenemases of OXA-48 (6.3%) and NDM-1-group (1.6%). Only 1.9% и 2.6% were insusceptible to aztreonam/avibactam and ceftazidime/avibactam correspondingly. Among non-β-lactam agents, the lowest resistance rates were observed with amikacin (16.6%), colistin (18.8%), tigecycline (23.5%) and fosfomycin (28.2%). Notably, 1.1% of the isolates were categorised as extensively drug-resistant (XDR).
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Institute of Antimicrobial Chemotherapy, Smolensk, Russia
Rozanova S.M., Perevalova E.YU., Yaranceva N.Z. (Ekaterinburg)
Novikova R.I., Moldovanu M.G. (Izhevsk)
Valiullina I.R., Nasybullova Z.Z. (Kazan)
Arhipenko M.V., Adonina E.E., Petrova L.V., Nizhegorodceva I.A. (Krasnodar)
Lazareva A.V., Kryzhanovskaya O.A., Popov D.A., Zemlyanoj A.B., Zubrickij V.F., Aleksandrova I.A. (Moscow)
Gordeeva S.A., CHernyavskaya YU.L. (Murmansk)
Kirillova G.SH. (Noyabrsk)
Popova L.D., Elohina E.V. (Omsk)
Markelova N.N., Smolkova YU.E. (Penza)
Anikina I.N. (Petrozavodsk)
Shigorceva N.G., Zykova T.A., Kucevalova O.YU., Panova N.I. (Rostov-on-Don)
Borisov A.M., Bozhkova S.A., Suborova T.N., Poluhina O.V. (Saint-Petersburg)
Krechikova O.I. (Smolensk)
Shetinin E.V. Alieva E.V. (Stavropol)
Martyanova N.M. (Tolyatti)
Vunukajnen T.M., Gudkova L.V., Volkovskaya I.V. (Tomsk)
Hohlyavin R.L., Habibrahmanova D.F. (Tyumen)
Burasova E.G., Hrebtovskaya V.A. (Ulan-Ude)
Molchanova I.V. (Chelyabinsk)
SHamaeva S.H., Portnyagina U.S., Bryzgalova V.I., Yadreeva O.N. (Yakutsk)
-
1.
Р1. Решедько ГК, Рябкова ЕЛ, Кречикова ОИ, и соавт. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клин микробиол антимикроб химиотер 2008;10:96-112.
-
2.
Sukhorukova M, Kozyreva V, Ivanchik N, Edelstein M, Kozlov R. Five-year trends in the prevalence and types of ESBLs and antimicrobial susceptibility of ESBL-producing nosocomial strains of Enterobacteriaceae in Russia. 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2010. Vienna, Austria. Abstract P716.
-
3.
Skleenova E, Sukhorukova M, Timokhova A, Martinovich A, Savochkina J, Edelstein M, Kozlov R. Sharp increase in carbapenem-non-susceptibility and carbapenemase production rates in nosocomial Gram-negative bacteria in Russia over the last decade. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2012, Denver, CO, USA. Abstract C2-1092.
-
4.
Эйдельштейн МВ, Склеенова ЕЮ, Шевченко ОВ и соавт. Распространенность и молекулярная эпидемиология грамотрицательных бактерий, продуцирующих металло-бета-лактамазы, в России, Беларуси и Казахстане. Клин микробиол антимикроб химиотер 2012;14:132-52.
-
5.
Сухорукова МВ, Эйдельштейн МВ, Склеенова ЕЮ, Иванчик НВ, Тимохова АВ, Дехнич АВ, Козлов РС. Антибиотикорезистентность нозокомиальных штаммов Enterobacteriaceae в стационарах России: результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011–2012 гг. Клин микробиол антимикроб химиотер 2014;16:254-65.
-
6.
Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
-
7.
Leclercq R, Canton R, Brown DF, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 2013;19:141-60.
-
8.
Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013;11:297-308.
-
9.
Edelstein M, Pimkin M, Palagin I, Edelstein I, Stratchounski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003;47:3724-32.
-
10.
Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014;15:1351-70.
-
11.
Canton R, Akova M, Carmeli Y, et al. European network on carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413-31.
-
12.
Shevchenko OV, Mudrak DY, Skleenova EY, Kozyreva VK, Ilina EN, Ikryannikova LN, Alexandrova IA, Sidorenko SV, Edelstein MV. First detection of VIM-4 metallo-β-lactamase-producing Escherichia coli in Russia. Clin Microbiol Infect 2012;18:E214-7.
-
13.
Ageevets VA, Partina IV, Lisitsyna ES, Ilina EN, Lobzin YV, Shlyapnikov SA, Sidorenko SV. Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. Int J Antimicrob Agents 2014 44:152-5.
-
14.
Barantsevich EP, Churkina IV, Barantsevich NE, Pelkonen J, Schlyakhto EV, Woodford N. Emergence of Klebsiella pneumoniae producing NDM-1 carbapenemase in Saint Petersburg, Russia. J Antimicrob Chemother 2013;68:1204-6.
-
15.
Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 2008;3:163-75.
-
16.
Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48(S1):5-16.
-
17.
ISO 20776-1:2006 "Clinical laboratory testing and in vitro diagnostic test systems - Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1 : Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases.
-
18.
Национальный Стандарт ГОСТ Р ИСО 20776-1-2010 Клинические лабораторные исследования и диагностические тест-системы in vitro. Исследование чувствительности инфекционных агентов и оценка функциональных характеристик изделий для исследования чувствительности к антимикробным средствам. Часть 1. Референтный метод лабораторного исследования активности антимикробных агентов против быстрорастущих аэробных бактерий, вызывающих инфекционные болезни.
-
19.
European Committee on Antimicrobial Susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Ver. 7.1 2017. Available at URL: http://www.eucast.org/clinical_breakpoints/
-
20.
Клинические рекомендации «Определение чувствительности микроорганизмов к Антимикробным препаратам». Версия 2015-02. Доступно по URL: http://www.antibiotic.ru/minzdrav/files/docs/clrec-dsma2015.pdf
-
21.
European Committee on Antimicrobial Susceptibility testing (EUCAST). EUCAST breakpoints for ceftazidime-avibactam. Available at URL: http://www.eucast.org/clinical_breakpoints/
-
22.
van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, Schouls LM. The Carbapenem inactivation method (CIM), a simple and lowcost alternative for the Carba NP test to assess phenotypic carbapenemase activity in Gram-negative rods. PLOS One 2015;10: e0123690.
-
23.
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.